Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

"We investigated the effects of maraviroc, the first approved CC-chemokine receptor 5 (CCR5) antagonist, on blood lipids in a post hoc analysis of the phase 3 MERIT study in treatment-naive patients. Methods: Patients received maraviroc 300 mg twice daily (n = 360) or efavirenz 600 mg once daily (n = 361), both in combination with zidovudine\/lamivudine, for up to 96 weeks. Baseline and on-treatment lipid profiles were analyzed according to National Cholesterol Education Program (NCEP) thresholds. Results: Baseline characteristics and lipid profiles were comparable between groups. Among patients with total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) below NCEP treatment thresholds at baseline, significantly more efavirenz- than maraviroc-treated patients exceeded those thresholds at 96 weeks (TC: 35% [74\/209] vs 11% [20\/188], P < .0001; LDL-c: 23% [47\/197] vs 8% [15\/183], P < .0001). Among patients exceeding NCEP thresholds at baseline, significantly more efavirenz- than maraviroc-treated patients exceeded the thresholds at 96 weeks (TC: 83% [24\/29] vs 50% [17\/34], P = .0084; LDL-c: 86% [19\/22] vs 55% [16\/29], P = .0314). Of those with baseline high-density lipoprotein cholesterol (HDL-c)